Amyloidβ-based therapy for Alzheimer’s disease:challenges,successes and future  

作　　者：Yun Zhang Huaqiu Chen Ran Li Keenan Sterling Weihong Song 

机构地区：[1]National Clinical Research Center for Geriatric Disorders,Xuanwu Hospital,Capital Medical University,Beijing,China [2]The Second Affiliated Hospital and Yuying Children’s Hospital,Institute of Aging,Key Laboratory of Alzheimer’s Disease of Zhejiang Province,Wenzhou Medical University,Wenzhou,Zhejiang,China [3]Townsend Family Laboratories,Department of Psychiatry,The University of British Columbia,Vancouver,BC V6T 1Z3,Canada [4]Oujiang Laboratory(Zhejiang Lab for Regenerative Medicine,Vision and Brain Health),Wenzhou,Zhejiang,China

出　　处：《Signal Transduction and Targeted Therapy》2023年第7期3374-3399,共26页信号转导与靶向治疗（英文）

基　　金：We thank Brian J.Song’s editing and comments.This work was supported by the National Natural Science Foundation of China(82201576);Beijing Hospitals Authority Youth Programme(QML20210804);Beijng Medical Research 2021-8(YZ);the National Natural Science Foundation of China(82150710557,82230043 and 82293642)to WS.WS was the Canada Research Chair in Alzhaimer’s Disease.

摘　　要：Amyloidβprotein(Aβ)is the main component of neuritic plaques in Alzheimer’s disease(AD),and its accumulation has been considered as the molecular driver of Alzheimer’s pathogenesis and progression.Aβhas been the prime target for the development of AD therapy.However,the repeated failures of Aβ-targeted clinical trials have cast considerable doubt on the amyloid cascade hypothesis and whether the development of Alzheimer’s drug has followed the correct course.

关 键 词：ALZHEIMER AΒ CLINICAL 

分 类 号：R749.16[医药卫生—神经病学与精神病学]